BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 3600676)

  • 1. Increased number of functionally defective large granular lymphocytes in lymphoma patients.
    Muhonen T; Teerenhovi L; Saksela E
    Nat Immun Cell Growth Regul; 1987; 6(2):57-64. PubMed ID: 3600676
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Natural killer activity and NK cytotoxic factors in peripheral blood and lymph node cells from non-Hodgkin's lymphoma patients.
    Nadkarni JJ; Mehta BA; Koppikar SB; Soman CS; Shrikhande SS; Advani SH
    Neoplasma; 1989; 36(6):701-8. PubMed ID: 2615873
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Surface markers and cytotoxic activity of blood natural killer cells studied at the single cell level in Hodgkin's disease.
    Jezewska E; Björkholm M; Giscombe R; Holm G; Tullgren O
    Clin Exp Immunol; 1985 Jul; 61(1):96-102. PubMed ID: 4042422
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Natural killer activity and antibody-dependent cellular cytotoxicity in patients with non-Hodgkin's lymphoma.
    Metha BA; Advani SH; Nadkarni SJ
    Neoplasma; 1988; 35(1):61-8. PubMed ID: 3352838
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [The natural killer cell activity and count of large granule-containing lymphocytes in the blood of patients with malignant lymphomas].
    Zlochevskaia LL; Kindzel'skiĭ LP; Shabaeva MM; Tsyganok TV
    Vrach Delo; 1990 Feb; (2):36-9. PubMed ID: 2339548
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reduced natural killer cell activity in non-hodgkin's lymphoma.
    Neri A; Brugiatelli M; Ozger Topuz U; Astaldi G
    Boll Ist Sieroter Milan; 1981 Nov; 60(5):394-407. PubMed ID: 7041921
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Defective natural cytotoxicity in patients with cancer: normal number of effector cells but decreased recycling capacity in patients with advanced disease.
    Steinhauer EH; Doyle AT; Reed J; Kadish AS
    J Immunol; 1982 Nov; 129(5):2255-9. PubMed ID: 7119445
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Interferon enhanced natural killer function in Hodgkin's disease.
    Levy S; Reins F; Aleksijevic A; Giron C; Oberling F; Mayer S; Lang JM
    Nouv Rev Fr Hematol (1978); 1986; 28(5):323-5. PubMed ID: 3808943
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Heat shock protein 90 inhibitor BIIB021 (CNF2024) depletes NF-kappaB and sensitizes Hodgkin's lymphoma cells for natural killer cell-mediated cytotoxicity.
    Böll B; Eltaib F; Reiners KS; von Tresckow B; Tawadros S; Simhadri VR; Burrows FJ; Lundgren K; Hansen HP; Engert A; von Strandmann EP
    Clin Cancer Res; 2009 Aug; 15(16):5108-16. PubMed ID: 19671844
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Natural killer (NK) activity in patients with Hodgkin's disease before, during and after multiple-agent therapy.
    Frydecka I; Kotlarek-Haus S; Kuliszkiewicz-Janus M; Kuliczkowski K
    Arch Immunol Ther Exp (Warsz); 1990; 38(5-6):407-14. PubMed ID: 2130805
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lysis of lymphoma cells by cultured large granular lymphocytes.
    Oshimi K; Oshimi Y; Naohara T; Mizoguchi H
    Exp Hematol; 1985 Dec; 13(11):1192-6. PubMed ID: 3877647
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Natural killer cells in normal pregnancy: analysis using monoclonal antibodies and single-cell cytotoxicity assays.
    Gregory CD; Lee H; Rees GB; Scott IV; Shah LP; Golding PR
    Clin Exp Immunol; 1985 Oct; 62(1):121-7. PubMed ID: 3864569
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Normal natural killer cell activity in Hodgkin's disease patients in remission.
    Douer D; Shaked N; Ramot B
    Clin Exp Immunol; 1987 Sep; 69(3):660-7. PubMed ID: 3665188
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The anti-lymphoma effect of antibody-mediated immunotherapy is based on an increased degranulation of peripheral blood natural killer (NK) cells.
    Fischer L; Penack O; Gentilini C; Nogai A; Muessig A; Thiel E; Uharek L
    Exp Hematol; 2006 Jun; 34(6):753-9. PubMed ID: 16728280
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Depressed natural killer cell activity in acute myocardial infarction.
    Klarlund K; Pedersen BK; Theander TG; Andersen V
    Clin Exp Immunol; 1987 Oct; 70(1):209-16. PubMed ID: 3500813
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunomodulation of early engrafted natural killer cells with interleukin-2 and interferon-alpha in autologous stem cell transplantation.
    Porrata LF; Inwards DJ; Lacy MQ; Markovic SN
    Bone Marrow Transplant; 2001 Oct; 28(7):673-80. PubMed ID: 11704790
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Activity of natural cytotoxic cells in non-Hodgkin's lymphoma].
    Frydecka I; Kotlarek-Haus S; Kuliczkowski K; Kuliszkiewicz-Janus M
    Pol Tyg Lek; 1992 Apr 20-27; 47(16-17):357-9. PubMed ID: 1437753
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mechanism of cell-mediated cytotoxicity at the single cell level. VI. Direct assessment of the cytotoxic potential of human peripheral blood non-lytic effector-target cell conjugates.
    Bonavida B; Lebow LT; Bradley TP
    J Immunol; 1984 Feb; 132(2):594-8. PubMed ID: 6606675
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Monocyte function in Hodgkin's disease.
    Holm G; Björkholm M; Johansson B; Mellstedt H; Lindemalm C
    Clin Exp Immunol; 1982 Jan; 47(1):162-8. PubMed ID: 7094420
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mechanisms of diminished natural killer cell activity in pregnant women and neonates.
    Baley JE; Schacter BZ
    J Immunol; 1985 May; 134(5):3042-8. PubMed ID: 3980989
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.